Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis

Ren, Yuqing; Wang, Ruizhi; Weng, Siyuan; Xu, Hui; Zhang, Yuyuan; Chen, Shuang; Liu, Shutong; Ba, Yuhao; Zhou, Zhaokai; Luo, Peng; Cheng, Quan; Dang, Qin; Liu, Zaoqu; Han, Xinwei

doi:10.1186/s12943-023-01831-w

Molecular Cancer

Table 3 Current mainstream clinical trials of four ROS-related cancer treatment measures

From: Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis

Conditions	Interventions	Phase	Status	Identifier
Cancer chemotherapy
Head and Neck Cancer	Cisplatin and XRT	Phase 2	Recruiting	NCT02994069
Bladder Cancer	Gemcitabine plus cisplatin	Not Applicable	Completed	NCT01801644
Melanoma	Elesclomol (STA-4783) and Paclitaxel	Phase 3	Terminated	NCT00522834
Breast Cancer	Paclitaxel followed by Doxorubicin	Phase 2	Completed	NCT00096291
Cancer radiotherapy
Breast Cancer	Radiation therapy	Not Applicable	Completed	NCT00836186
Lung Cancer	Radiation therapy	Phase 2	Completed	NCT01055197
Primarily Resectable Pancreatic Cancer	Neoadjuvant photon radiation	Not Applicable	Completed	NCT01027221
Pancreatic Cancer	Radiation and Anti-PD-1 Antibody	Phase 2	Unknown	NCT03374293
Photodynamic therapy
Non Small Cell Lung Cancer	Photodynamic Therapy	Not Applicable	Terminated	NCT03564054
Advanced Rectal Cancer	Photodynamic Therapy	Phase 2/3	Suspended	NCT01872104
Colon Cancer	PDT with 5-ALA radiosensitization	Phase1/2	Withdrawn	NCT01522677
Immunotherapy
Extensive stage small-cell lung cancer (ES SCLC)	Thoracic radiotherapy and immune checkpoint inhibitors (ICI)	Phase 3	Recruiting	NCT05223647
Bladder Cancer	Anti-PD-1 (Nivolumab)	Phase 1	Terminated	NCT03106610
Colorectal Cancer Stage III	Anti-PD-1 antibody-activated TILs	Phase1/2	Unknown	NCT03904537
Esophageal Neoplasms	An anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor	Not Applicable	Recruiting	NCT05349045
Locally Advanced and Metastatic Pancreatic Cancer	PD-L1/CTLA4 BsAb	Phase1/2	Recruiting	NCT04324307
Breast Cancer	Anti PD-L1 Antibody + Anti CTLA-4 Antibody	Phase 2	Terminated	NCT03430466
Stage 0/1 Breast Cancer	IV/oral n-acetylcysteine	Phase 1	Completed	NCT01878695
Bladder Cancer	Dendritic cells	Phase 2	Completed	NCT04184232
Renal Cancer	Dendritic Cell Tumor Fusion Vaccine + Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)	Phase1/2	Active, not recruiting	NCT00458536
Refractory Metastatic Colorectal Cancer	NKG2D CAR-NK	Phase 1	Recruiting	NCT05213195

Abbreviations: XRT X-Ray Therapy, PD-1 Programmed cell death protein 1, ICI Immune checkpoint inhibitors, 5-ALA 5-aminolevulinic acid, ES SCLC Extensive stage small-cell lung cancer, TLR Toll-like receptor, PD-L1 Programmed death-ligand 1, CTLA-4 Cytotoxic T-lymphocyte-associated protein 4, BsAb Bispecific monoclonal antibody

Back to article page

ISSN: 1476-4598

Contact us

General enquiries: journalsubmissions@springernature.com